Axcella Reports Positive Phase 2a Study Results Of Its Drug AXA1125 For Long COVID

Axcella Therapeutics (AXLA) on Tuesday reported positive topline results from the Phase 2a study of its drug candidate AXA1125 in patients with fatigue related to Long Covid.

In the Phase 2a study, 41 subjects were divided into two groups to receive AXA1125 by one group and placebo by the other.

Topline results from the study showed statistically significant improvement in mental and physical fatigue scores in people with Long Covid who were treated with AXA1125 for 28 days. They also showed improved scores in a 6 minute walk test.

There was no significant adverse events reported by study subjects, the company said.

"We are delighted to report that we have meaningful clinical results as well as an increased understanding on the best endpoints for future, potentially registrational studies and look forward to engaging with the regulatory authorities around the next steps in clinical development," said Bill Hinshaw, CEO of Axcella.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Walt Disney's streaming service Disney+ is rolling out its much-anticipated new ad-supported subscription plan for Disney+ in the U.S. as part of its bid to stem the loss and make its streaming business profitable after the services posted a hefty operating loss of more than $1 billion in the third quarter. It is also raising pricing for its bundled subscription plans with Hulu, ESPN+ and live TV. The U.S. Food and Drug Administration announced the intended availability of base powder to make around 6 million bottles of specialty formula from Mexico as part of its efforts to meet the nationwide supply shortage caused by Abbott Nutrition recall. Reckitt Nutrition/Mead Johnson Nutrition will send an initial shipment of 331 thousand pounds of base powder for PurAmino Hypoallergenic Formula. Shares of Deutsche Telekom AG were gaining more than 1 percent in the morning trading in Germany after the telecom major on Thursday raised its fiscal 2022 earnings outlook again, despite reporting lower profit in its second quarter. Adjusted EBITDA AL, a key earnings metric, increased, while adjusted EBITDA AL margin dropped.
Follow RTT